Product Name :
Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody
EN
Lymphocyte Activation Gene 3, LAG3, CD223, Cluster of Differentiation 223
Source:
The anti-human LAG-3 monoclonal antibody relatlimab biosimilar was produced in mammalian cells.
Molecular Weight:
Activity :
Purity:
>95% by SDS-PAGE under reducing conditions and HPLC.
Endotoxin :
< 1 EU per 1 mg of the protein by the LAL method.
Formulation:
Reconstitution :
Shipping:
The research grade relatlimab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
/strong>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Form of Antibody :
0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Clone:
Isotype:
Human IgG4 kappa.
Background:
What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3–blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer. Relatlimab and the anti–PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti–PD-1 monotherapy. Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins: Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars: Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Additional Information:
| Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody Recombinant Humanized IgG4 Monoclonal Antibody. |Isotype: Human IgG4 kap|The anti-human LAG-3 monoclonal antibody relatlimab biosimilar was produced in mammal cells. |Specificity/Sensitivity: The in vivo grade relatlimab biosimilar specifically binds to the human lymphocyte-activation gene 3 (LAG-3). |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives. |Endotoxin: |Purity: >95% by SDS-|The research grade relatlimab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is relatlimab biosimilar research grade? Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potent promote an anti-tumor response. LAG-3 is a component of an immune checkpoint |Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody S|Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
3-Nitrotyrosine Antibody
p53 (acetyl K370)Antibody
Parkin Antibody: Parkin Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 52 kDa, targeting to Parkin. It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.
